These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37190949)

  • 1. Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis.
    Karna R; S Deliwala S; Ramgopal B; Asawa P; Mishra R; P Mohan B; Jayakrishnan T; Grover D; Kalra T; Bhalla J; Saraswati U; K Gangwani M; Dhawan M; G Adler D
    Immunotherapy; 2023 Jul; 15(10):773-786. PubMed ID: 37190949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
    BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
    Mei T; Wang T; Deng Q; Gong Y
    Front Immunol; 2023; 14():1062679. PubMed ID: 36825025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digestive Toxicities Secondary to Immune Checkpoint Inhibition Therapy - Reports of Rare Events. A Systematic Review.
    Radulescu L; Crisan D; Grapa C; Radulescu D
    J Gastrointestin Liver Dis; 2021 Dec; 30(4):506-516. PubMed ID: 34752584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
    Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
    Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors.
    Fukushima T; Kobayashi S; Ueno M
    Jpn J Clin Oncol; 2024 Sep; 54(9):949-958. PubMed ID: 38769817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of immune checkpoint inhibitor-related adverse events: A review of case reports.
    Si X; Song P; Ni J; Di M; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Yang X; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):498-504. PubMed ID: 31970923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.
    Patel NS; Oury A; Daniels GA; Bazhenova L; Patel SP
    Oncologist; 2018 Oct; 23(10):1236-1241. PubMed ID: 29769383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
    Guo Q; Gao J; Guo H; Xie J; Cheng J
    Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Takada S; Hirokazu H; Yamagishi K; Hideki S; Masayuki E
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1697-1699. PubMed ID: 32592366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
    Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
    Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Zhang W; Gu J; Bian C; Huang G
    Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
    Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
    Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.